Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,122 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Disease Severity Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

Low-Intensity Physical Therapy for Prevention of Pre and Postpartum Urinary Incontinence

NCT00178282
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Pelvic Floor Muscle exercises
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2011 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis

NCT06257537
View directory record Official record
Conditions
Osteo Arthritis Knee, Arthritis
Interventions
Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, 2.5% Diclofenac Patches, SAM Patch
Device · Drug · Other
Lead sponsor
ZetrOZ, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Stamford, Connecticut • Trumbull, Connecticut • Dryden, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

NCT06455202
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
barzolvolimab, Matching placebo
Biological
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
63
States / cities
Cullman, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

NCT00253513
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
fludarabine, treosulfan, allogeneic blood or bone marrow transplantation
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Reduced Intensity Haploidentical Transplant for Hematological Malignancies

NCT01162096
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Haploidentical Allogeneic Transplantation
Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 1Phase 2 Interventional

Reduced Intensity Transplant Using Extracorporeal Photopheresis

NCT00179790
View directory record Official record
Conditions
Leukemia, Cancer
Interventions
Extracorporeal Photopheresis
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Jul 22, 2026, 2:48 PM EDT
Terminated Phase 1 Interventional Results available

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

NCT06056310
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Xevinapant, Cisplatin, intensity-modulated radiation therapy (IMRT)
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Miami Beach, Florida • Detroit, Michigan • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

NCT00047060
View directory record Official record
Conditions
Mycosis Fungoides, Sezary Syndrome
Interventions
A matched peripheral donor stem cells, cyclosporine, fludarabine, Campath
Other · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Not applicable Interventional

Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD)

NCT06612788
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Exablate Model 4000 Type 2.0/2.1
Device
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 1 Interventional

Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

NCT02996773
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Lymphoma,Non-Hodgkin, Lymphoma, Hodgkin, Lymphoma, Follicular, Marginal Zone Lymphoma, Large Cell Lymphoma, Mantle-Cell Lymphoma, Gray Zone Lymphoma, Burkitt Lymphoma, High Risk Undifferentiated Acute Leukemia
Interventions
Bendamustine, Cyclophosphamide
Drug
Lead sponsor
University of Arizona
Other
Eligibility
4 Years to 30 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 22, 2026, 2:48 PM EDT
Active, not recruiting Phase 2 Interventional

Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

NCT05364762
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Cyclophosphamide, Itacitinib, Peripheral Blood Stem Cell Transplantation, Quality-of-Life Assessment, Tacrolimus
Drug · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101

NCT05629741
View directory record Official record
Conditions
Community-acquired Pneumonia, Bacterial Pneumonia
Interventions
CMTX-101, Placebo
Drug
Lead sponsor
Clarametyx Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
8
States / cities
Augusta, Georgia • Idaho Falls, Idaho • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Jul 22, 2026, 2:48 PM EDT
Not listed Phase 3 Interventional

Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer

NCT00022373
View directory record Official record
Conditions
Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity
Interventions
iseganan HCl oral solution, management of therapy complications
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant

NCT01244906
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation
Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Jul 22, 2026, 2:48 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Trial Evaluating Elimination of Radiation Therapy

NCT00593840
View directory record Official record
Conditions
Cancer of the Larynx
Interventions
Intensity modulated radiation therapy
Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Completed No phase listed Observational

Association Between Cytokines and Severity of Respiratory Syncytial Virus (RSV)-Induced Illness in the Elderly

NCT00609635
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Not listed
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
65 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2009 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Not applicable Interventional

A Comparison: High Intense Periodic vs. Every Week Therapy in Children With Cerebral Palsy (ACHIEVE)

NCT02897024
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Physical Therapy
Other
Lead sponsor
Ohio State University
Other
Eligibility
2 Years to 8 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Jul 22, 2026, 2:48 PM EDT
Completed No phase listed Observational

Forward Looking InfraRed Imaging and Severity Score in Complex Regional Pain Syndrome

NCT05852210
View directory record Official record
Conditions
CRPS (Complex Regional Pain Syndromes)
Interventions
Infrared Imaging
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

NCT04607980
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ABP 654, Ustekinumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 3 Interventional

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

NCT00075868
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Drug/Agent Toxicity by Tissue/Organ, Radiation Enteritis
Interventions
octreotide acetate, Placebo
Drug · Other
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
112
States / cities
Mobile, Alabama • Phoenix, Arizona • Chico, California + 89 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer

NCT00911118
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma
Interventions
Hypofractionated, image-guided, intensity-modulated external beam radiation
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
7
States / cities
Commack, New York • Harrison, New York • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Relationship Between Diet, Lifestyle, and the Severity of Coronary Artery Disease

NCT02382250
View directory record Official record
Conditions
Dietary Habits, Coronary Artery Disease, Lifestyle
Interventions
Survey
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Jul 22, 2026, 2:48 PM EDT
Terminated Phase 2 Interventional Results available

Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal

NCT05114460
View directory record Official record
Conditions
Opioid Overdose
Interventions
Naloxone, Marijuana
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jul 22, 2026, 2:48 PM EDT